Don’t fall for the distraction of tariffs. To reduce fentanyl deaths, we need to get opioid users into treatment and reduce the prescribing of opioids ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Discover how innovative physical therapy, smart medications, nutrition strategies and mind-body techniques are transforming ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

The Food and Drug Administration (FDA) has granted Fast Track designation to LTG-001 for the treatment of acute pain. LTG-001, an oral Nav1.8 selective ...

The U.S. Food and Drug Administration recently approved a new class of non-opioid painkiller which one Lowcountry pharmacist is calling “revolutionary.” ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

Tris Pharma’s first-in-class oral dual-NMR agonist achieved its primary endpoint in the ALLEVIATE-2 study by demonstrating a ...

The popular painkiller Advil has been increasingly targeting the running community, partnering with influencers to promote ...

Topline results were announced from a phase 3 trial evaluating cebranopadol for the treatment of moderate to severe acute pain in patients following ...

Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.

The Sopranos' actress Jamie-Lynn Sigler, 43, remembers nights when she ‘fell apart, terrified’ fearing her son Beau 'was ...